Targeting the thyroid gland with thyroid-stimulating hormone (TSH)-nanoliposomes
Source abstract
Abstract
Various tissue-specific antibodies have been attached to nanoparticles to obtain targeted delivery. In particular, nanodelivery systems with selectivity for breast, prostate and cancer tissue have been developed. Here, we have developed a nanodelivery system that targets the thyroid gland. Nanoliposomes have been conjugated to the thyroid-stimulating hormone (TSH), which binds to the TSH receptor (TSHr) on the surface of thyrocytes. The results indicate that the intracellular uptake of TSH-nanoliposomes is increased in cells expressing the TSHr. The accumulation of targeted nanoliposomes in the thyroid gland following intravenous injection was 3.5-fold higher in comparison to untargeted nanoliposomes. Furthermore, TSH-nanoliposomes encapsulated with gemcitabine showed improved anticancer efficacy in vitro and in a tumor model of follicular thyroid carcinoma. This drug delivery system could be used for the treatment of a broad spectrum of thyroid diseases to reduce side effects and improve therapeutic efficacy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Monoclonal and Polyclonal Antibodies Research · nanoparticles nucleation surface interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (37)
Show source-provided references
1. Nanoliposome-encapsulated anticancer drugs: still waiting for the magic bullet?10.2174/092986709789712916 ↗
2. Cancer nanotechnology: opportunities and challenges10.1038/nrc1566 ↗
3. Shape-specific polymeric nanomedicine: emerging opportunities and challenges10.1258/ebm.2010.010243 ↗
4. Polyaspartylhydrazide copolymer-based supramolecular vesicular aggregates as delivery devices for anticancer drugs10.1021/bm700964a ↗
5. Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity10.1517/17425247.2011.632630 ↗
6. In vivo activity of gemcitabine-loaded PEGylated small unilamellar nanoliposomes against pancreatic cancer10.1007/s00280-009-0957-1 ↗
7. Anticancer activity of liposomal bergamot essential oil (BEO) on human neuroblastoma cells10.1016/j.colsurfb.2013.09.017 ↗
8. Sustained zero-order release of intact ultra-stable drug-loaded nanoliposomes from an implantable nanochannel delivery system10.1002/adhm.201300188 ↗
9. State of the art in PEGylation: the great versatility achieved after forty years of research10.1016/j.jconrel.2011.10.037 ↗
10. PEGylation for improving the effectiveness of therapeutic biomolecules10.1358/dot.2009.45.9.1416421 ↗
11. Shrinkage of pegylated and non-pegylated nanoliposomes in serum10.1016/j.colsurfb.2013.10.009 ↗
12. Liposomal chemotherapeutics10.2217/fon.13.146 ↗
13. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage10.1016/j.jconrel.2009.02.002 ↗
14. Multifunctional PEGylated 2C5-immunonanoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity10.1016/j.jconrel.2011.12.002 ↗
15. Folate-targeted supramolecular vesicular aggregates as a new frontier for effective anticancer treatment in in vivo model10.1016/j.ejpb.2012.06.001 ↗
16. Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugs10.1016/j.biomaterials.2010.05.060 ↗
17. Targeting the thyrotropin receptor in thyroid disease10.1517/14728222.2012.692779 ↗
18. Expression of the Na+/I− symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes
19. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism10.1210/jc.2006-2707 ↗
20. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients10.1038/ncpendmet0449 ↗
21. Human thyrotropin receptor gene-expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation10.1016/0303-7207(91)90018-N ↗
22. Semi-quantitative comparison of the differentiation markers and sodium iodide symporter messenger ribonucleic acids in papillary thyroid carcinomas using RT-PCR10.1530/eje.0.1420340 ↗
23. Correlation between the loss of thyroglobulin iodination and the expression of thyroid-specific proteins involved in iodine metabolism in thyroid carcinomas10.1210/jc.2003-030586 ↗
24. Gel-free sample preparation for the nanoscale LC-MS/MS analysis and identification of low-nanogram protein samples
25. Ethosomes for skin delivery of ammonium glycyrrhizinate: in vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteers10.1016/j.jconrel.2005.04.007 ↗
26. Studies on the role of amino acids 38-45 in the expression of a functional thyrotropin receptor
27. Inhibition of tumorigenesis by the thyroid hormone receptor β in xenograft models10.1089/thy.2013.0054 ↗
28. Supramolecular devices to improve the treatment of brain diseases10.1016/j.drudis.2011.02.006 ↗
29. Nanoparticulate devices for brain drug delivery10.1002/med.20201 ↗
30. Gemcitabine-loaded PEGylated unilamellar nanoliposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity10.1016/j.jconrel.2010.02.021 ↗
31. Cytotoxic effects of gemcitabine-loaded nanoliposomes in human anaplastic thyroid carcinoma cells10.1186/1471-2407-4-63 ↗
32. Improved in vitro anti-tumoral activity, intracellular uptake and apoptotic induction of gemcitabine-loaded pegylated unilamellar nanoliposomes10.1166/jnn.2008.065 ↗
33. Nanoliposomes in biology and medicine10.1007/978-0-387-76713-0_9 ↗
34. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer10.2217/17435889.3.6.761 ↗
35. Gemcitabine and tamoxifen-loaded nanoliposomes as multidrug carriers for the treatment of breast cancer diseases10.1016/j.ijpharm.2011.10.056 ↗
36. Recent advances with nanoliposomes as pharmaceutical carriers10.1038/nrd1632 ↗
37. The safety and efficacy of antithyroid drugs10.1517/14740338.5.1.107 ↗